Show simple item record

dc.contributor.authorErtesvåg, Nina Urke
dc.contributor.authorIversen, Arild
dc.contributor.authorBlomberg, Bjørn
dc.contributor.authorÖzgümüs, Türküler
dc.contributor.authorRijal, Pramila
dc.contributor.authorFjelltveit, Elisabeth Berg
dc.contributor.authorCox, Rebecca Jane
dc.contributor.authorLangeland, Nina
dc.contributor.authorHaug, Kjell
dc.contributor.authorSandnes, Helene Heitmann
dc.contributor.authorMohn, Kristin Greve-Isdahl
dc.contributor.authorOlofsson, Jan Stefan
dc.contributor.authorSævik, Marianne
dc.contributor.authorBrokstad, Christopher James
dc.contributor.authorKuwelker, Kanika
dc.contributor.authorHeienberg, Kristin
dc.date.accessioned2023-10-10T06:29:22Z
dc.date.available2023-10-10T06:29:22Z
dc.date.created2023-07-03T11:37:20Z
dc.date.issued2023
dc.identifier.issn2352-3964
dc.identifier.urihttps://hdl.handle.net/11250/3095348
dc.description.abstractBackground: The burden of COVID-19 in children and adolescents has increased during the delta and omicron waves, necessitating studies of long-term symptoms such as fatigue, dyspnoea and cognitive problems. Furthermore, immune responses in relation to persisting symptoms in younger people have not been well characterised. In this cohort study, we investigated the role of antibodies, vaccination and omicron reinfection upon persisting and long-term symptoms up to 8 months post-delta infection. Methods: SARS-CoV-2 RT-PCR positive participants (n = 276, aged 10–20 years) were prospectively recruited in August 2021. We recorded the major symptoms of post COVID-19 condition and collected serum samples 3- and 8-months post delta infection. Binding antibodies were measured by spike IgG ELISA, and surrogate neutralising antibodies against Wuhan and delta variants by the hemagglutination test (HAT). Findings: After delta infection, persisting symptoms at 3 months were significantly associated with higher delta antibody titres (OR 2.97, 95% CI 1.57–6.04, p = 0.001). Asymptomatic acute infection compared to symptomatic infection lowered the risk of persisting (OR 0.13, 95% CI 0.02–0.55, p = 0.013) and long-term (OR 0.28 95% CI 0.11–0.66, p = 0.005) symptoms at 3 and 8 months, respectively. Adolescents (16–20 years) were more likely to have long-term symptoms compared to children (10–15 years) (OR 2.44, 95% CI 1.37–4.41, p = 0.003). Interpretation: This clinical and serological study compares long-term symptoms after delta infection between children and adolescents. The association between high antibody titres and persisting symptoms suggest the involvement of an immune mechanism. Similarly to adults, the dominant long-term symptoms in children are fatigue, dyspnoea and cognitive problems.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titlePost COVID-19 condition after delta infection and omicron reinfection in children and adolescentsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 the authorsen_US
dc.source.articlenumber104599en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.ebiom.2023.104599
dc.identifier.cristin2160296
dc.source.journalEBioMedicineen_US
dc.identifier.citationEBioMedicine. 2023, 92, 104599.en_US
dc.source.volume92en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal